Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is proud to announce the launch of its D
The Nobel Prize in Physiology or Medicine awarded
This year, the Hamburg based life sciences company
Alembic Pharmaceuticals Ltd., t
Since it’s an ingredient in so many foods, you h
Dear Readers, Welcome to the latest issue of Micr
Alkermes plc announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the company’s New Drug Application (NDA) resubmission for ALKS 3831 (olanzapine/samidorphan) for the treatment of adults with schizophrenia and adults with bipolar I disorder, and has assigned the application a new Prescription Drug User Fee Act (PDUFA) target action date of June 1, 2021.
The FDA classified the resubmission as a complete, Class 2 response to the Complete Response Letter (CRL) issued in November 2020, following a remote review of records requested under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (the “FDCA”) relating to the manufacture of ALKS 3831 at the company’s Wilmington, OH facility. Subsequent to Alkermes’ resubmission of the NDA, the FDA issued a new request for records under Section 704(a)(4) of the FDCA to supplement the information previously provided by the company. Neither the CRL nor this subsequent records request identified or raised any concerns about the clinical or non-clinical data in the NDA and the FDA has not asked Alkermes to complete any new clinical trials to support approval of the application.
Alkermes will continue to work closely with the FDA as it completes its review of the ALKS 3831 NDA and remains committed to making ALKS 3831 available to patients as quickly as possible.
